Blastic transformation of chronic myelogenous leukemia (CML) is characterized by the presence of nonrandom, secondary genetic abnormalities in the majority of Philadelphia1 clones, and loss of p53 tumor suppressor gene function is usually a consistent obtaining in 25C30% of CML blast crisis patients. cells produced a transplantable, highly aggressive, poorly differentiated acute myelogenous leukemia. In… Continue reading Blastic transformation of chronic myelogenous leukemia (CML) is characterized by the